Yifan Pharmaceutical Co.Ltd(002019)
Prior approval opinions of independent directors on matters related to the 23rd Meeting of the seventh board of directors of the company
As an independent director of the seventh board of directors of Yifan Pharmaceutical Co.Ltd(002019) (hereinafter referred to as “the company”), in accordance with the provisions of the rules for independent directors of listed companies, the Listing Rules of Shenzhen Stock Exchange and the articles of association, I hereby express my prior approval opinions on the relevant matters of the 23rd Meeting of the seventh board of directors of the company, as follows:
1、 Prior approval opinions on the proposal on renewing the appointment of Lixin Certified Public Accountants (special general partnership) as the audit institution of the company in 2022
We believe that Lixin Certified Public Accountants (special general partnership) has rich experience and professional quality in the audit business of listed companies, and has demonstrated professional ability and diligence in the audit work of the company in 2021. We agree to renew the appointment of Lixin Certified Public Accountants (special general partnership) as the audit institution of the company in 2022 for one year, And agreed to submit this proposal to the 23rd Meeting of the seventh board of directors for deliberation.
2、 Prior approval opinions on the proposal on continuing to accept the guarantee and related party transactions provided by the controlling shareholders and actual controllers of the company for the company’s bank loans
In order to support the development of the company and solve the problem of providing guarantee for the company’s bank loans, Mr. Cheng Xianfeng, the controlling shareholder and actual controller of the company, plans to provide guarantee for the company’s bank loans with a total amount of no more than 2 billion yuan with his personal credit or company shares. For this guarantee, the company does not need to pay any guarantee fee to the controlling shareholder and actual controller of the company, nor does it need to provide any form of counter guarantee. This guarantee does not damage the rights and interests of the company and minority shareholders.
We believe that the behavior of the controlling shareholders and actual controllers of the company providing guarantee for the company’s bank loans constitutes a connected transaction, and agree to submit the proposal on accepting the guarantee and connected transaction provided by the controlling shareholders and actual controllers of the company for the company’s bank loans to the 23rd Meeting of the seventh board of directors of the company for deliberation.
[there is no text on this page, which is the signature page of independent directors’ prior approval opinions on relevant matters of the 23rd Meeting of Yifan Pharmaceutical Co.Ltd(002019) the seventh board of directors.] Signature of independent director:
Genhong Cheng Lei Xintu Liu Hongquan
April 13, 2022
